Praxis Precision Medicines, Inc.

Equities

PRAX

US74006W2070

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
54.8 ^USD	+3.63%		+16.87%	+145.96%

Apr. 11	Certain Common Stock of Praxis Precision Medicines, Inc. are subject to a Lock-Up Agreement Ending on 11-APR-2024.	CI
Apr. 11	Certain Restricted Stock Units of Praxis Precision Medicines, Inc. are subject to a Lock-Up Agreement Ending on 11-APR-2024.	CI

Praxis Precision Medicines, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

March 05, 2024 at 07:13 am EST

Praxis Precision Medicines, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 123.28 million compared to USD 214.03 million a year ago. Basic loss per share from continuing operations was USD 18.69 compared to USD 69.65 a year ago.

Latest news about Praxis Precision Medicines, Inc.

Certain Common Stock of Praxis Precision Medicines, Inc. are subject to a Lock-Up Agreement Ending on 11-APR-2024.	Apr. 10	CI
Certain Restricted Stock Units of Praxis Precision Medicines, Inc. are subject to a Lock-Up Agreement Ending on 11-APR-2024.	Apr. 10	CI
Certain Stock Options of Praxis Precision Medicines, Inc. are subject to a Lock-Up Agreement Ending on 11-APR-2024.	Apr. 10	CI
Wedbush Trims Price Target on Praxis Precision Medicines to $40 From $41 After $200 Million Secondary Offering, Maintains Neutral Rating	Apr. 08	MT
Praxis Precision Medicines Prices $200 Million Public Offering	Mar. 28	MT
Praxis Precision Medicines Plans Public Equity Offering	Mar. 27	MT
Jefferies Adjusts Praxis Precision Medicines' Price Target to $128 From $75, Keeps Buy Rating	Mar. 26	MT
Transcript : Praxis Precision Medicines, Inc. - Special Call	Mar. 26
Praxis Precision Medicines Reports Positive Results of PRAX-628 Study Evaluating Photo Paroxysmal Response Achieving 100% Response in Treated Patients	Mar. 26	CI
Praxis Precision Medicines Files $750 Million Mixed-Securities Shelf Registration	Mar. 05	MT
Wedbush Adjusts Praxis Precision Medicines' Price Target to $41 From $29, Maintains Neutral Rating	Mar. 05	MT
Praxis Precision Medicines, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 05	CI
Praxis Precision Medicines, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 05	CI
North American Morning Briefing : Rate Doubts Keep -2-	Feb. 06	DJ
Praxis Precision Medicines Prices $150 Million Public Offering of Shares, Warrants; Shares Rise	Jan. 11	MT
Sector Update: Health Care Stocks Mixed Premarket Thursday	Jan. 11	MT
Praxis Precision Medicines Plans Public Offering of Common Stock, Warrants; Shares Down Pre-Bell	Jan. 11	MT
Praxis Precision Medicines, Inc. Provides Update on Advancing Clinical Stage Portfolio	Jan. 08	CI
Praxis Precision Signs License Deal With Tenacia for Ulixacaltamide in Greater China	Jan. 05	MT
Praxis Precision Medicines Announces Licensing and Collaboration Agreement with Tenacia Biotechnology for Ulixacaltamide in Greater China	Jan. 05	CI
Wedbush Adjusts Praxis Precision Medicines' Price Target to $16 From $15 After Reverse Stock Split, Keeps Neutral Rating	Nov. 30	MT
Praxis Precision Medicines, Inc. Receives PRIME Designation from the EMA for elsunersen (PRAX-222) for Treatment of SCN2A Gain of Function Developmental Epilepsies	Nov. 16	CI
Praxis Precision Medicines Says its Elsunersen Receives EMA's PRIME Designation for Potential Epilepsy Treatment	Nov. 16	MT
Wedbush Trims Praxis Precision Medicines' PT to $1 From $2 After 'Relatively Uneventful' Q3 Results; Keeps Neutral Rating	Nov. 07	MT
Praxis Precision Medicines, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI

Chart Praxis Precision Medicines, Inc.

Duration

Period

More charts

Company Profile

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company. It is focused on translating insights from genetic epilepsies into the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is applying genetic insights to the discovery and development of therapies for neurological disorders through two platforms, using its understanding of shared biological targets and circuits in the brain. Its platform includes Cerebrum, a small molecule platform, which utilizes deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies, and Solidus, is an antisense oligonucleotide platform, is an efficient, targeted precision medicine discovery and development engine anchored on a proprietary, computational methodology. Its product candidates include ulixacaltamide, PRAX-562, PRAX-628 and elsunersen.

Sector

Biotechnology & Medical Research

Calendar

2024-05-07 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Praxis Precision Medicines, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

54.8 USD

Average target price

138.6 USD

Spread / Average Target

+152.92%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
PRAXIS PRECISION MEDICINES, INC.	+145.96%	907M
IQVIA HOLDINGS INC.	+1.51%	42.75B
MODERNA, INC.	+8.57%	41.34B
LONZA GROUP AG	+49.22%	41.61B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research